WO2001000869A2 - Arrangements de sequences nucleotidiques - Google Patents

Arrangements de sequences nucleotidiques Download PDF

Info

Publication number
WO2001000869A2
WO2001000869A2 PCT/IL2000/000370 IL0000370W WO0100869A2 WO 2001000869 A2 WO2001000869 A2 WO 2001000869A2 IL 0000370 W IL0000370 W IL 0000370W WO 0100869 A2 WO0100869 A2 WO 0100869A2
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotides
catalytic
catalytic activity
sequence
nucleic acid
Prior art date
Application number
PCT/IL2000/000370
Other languages
English (en)
Other versions
WO2001000869A3 (fr
Inventor
Asher Nathan
Original Assignee
Intelligene Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intelligene Ltd. filed Critical Intelligene Ltd.
Priority to EP00939029A priority Critical patent/EP1194573A2/fr
Priority to JP2001506860A priority patent/JP2003503068A/ja
Priority to AU54238/00A priority patent/AU5423800A/en
Publication of WO2001000869A2 publication Critical patent/WO2001000869A2/fr
Publication of WO2001000869A3 publication Critical patent/WO2001000869A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips

Definitions

  • the present invention concerns arrays of nucleic acid sequences and methods of detection using said arrays.
  • the present invention further concerns a method for detecting an analyte in cells, as well as a method for gene therapy.
  • arrays of different nucleic acid sequences wherein the sequences have a predefined spatial arrangement so that the location of each sequence is known, are used for hybridization-based detection purposes. These arrays, contain a plurality of different oligonucleotides, which are complementary, to some degree, to oligonucleotides which are to be detected in a sample. Then, the array is brought into contact with the sample under conditions allowing hybridization of nucleic acid sequences, and the presence of hybridization complexes is detected, for example, by using fluorescent labels.
  • the arrays of oligonucleotides are present as "biochip ", i.e. an array of oligonucleotides arranged in a very small area. Using developed robotic techniques for micro-patterning of biological molecules, the predetermined arrangement of oligonucleotide sequences can be packed to a single biochip the size of an electric microchip which may be read and analyzed by a computer.
  • the nucleic acid hybridization-based arrays are used for a plurality of detection purposes, such as multiplexing detection of many different sequences in a sample, sequencing of longer sequences by hybridization (SBH), etc.
  • nucleic acid sequences arrays are based on probes for hybridization to complementary sequences.
  • Catalytic nucleic acid sequences notably ribozymes
  • ribozymes are molecules, typically RNA molecules, which have enzyme-like catalytic activities associated with cleavage, splicing or ligation of nucleic acid sequences.
  • the typical substrates for ribozymes catalytic activities are RNA molecules, although ribozymes may catalyze reactions in which DNA molecules (or even amino acids) serve as substrates.
  • ribozymes in order to treat diseases or genetic disorders by cleaving a target RNA, such as viral RNA or messenger RNA transcribed from genes that should be turned off. This was proposed as an alternative to blockage of the RNA transcript by the use of antisense sequences. Owing to the catalytic nature of the ribozyme, a single ribozyme molecule cleaves many molecules of target RNA and therefore therapeutic activity is achieved in relatively lower concentrations than those required for antisense treatment (WO 96/23569). However, in all cases, the ribozyme acts directly on the viral RNA directly.
  • WO 94/13833 describes a method for detecting nucleic acid molecules in a solution by tailoring a specific ribozyme molecule having two regions, one complementary to the nucleic acid sequence to be detected, and the other complementary to a co-target molecule bearing a detectable label.
  • the ribozyme is able to specifically and reversibly bind both to a selected target nucleic acid sequence and to the labelled co-target.
  • the ribozyme undergoes a conformational change which renders it active, and in its active condition it is able to cleave the label of the co-target, and the free label can then be detected.
  • the ribozyme Upon cleavage of the co-target, the ribozyme is able to re-associate with an additional co-target, cleaving more label and producing more detectable signals.
  • WO 98/08974 concerns a nucleic acid molecule termed "proto- nucleozyme” that has a priori no catalytic activity but which becomes catalytically active by formation of a complex with a co-factor to form a catalytically active complex termed "nucleozyme ".
  • a proto-nucleozyme is in fact a nucleozyme with a missing component, which missing component is completed by the co-factor.
  • the complex between the proto-nucleozyme and the co-factor may also at times be referred to as "catalytic complex" and is in fact a nucleozyme since it has catalytic activity.
  • the proto-nucleozyme may consist of deoxynucleotides (dNTP's), ribo-nucleotides (rNTP's), as well as other nucleotides such as 2 -O-methyl nucleotides, or any combinations of these.
  • Oligonucleotide a sequence of nucleotides. May be composed entirely of dNTP's, rNTP's or a combination of both, and may comprise non-naturally occurring nucleotides such as 2'-0'-methyl nucleotides or a combination of the above.
  • Oligonucleotide species - a plurality of oligonucleotide molecules featuring essentially the same nucleotide sequence. Each oligonucleotide specie has a different sequence different from that of another oligonucleotide sequence.
  • Catalytic oligonucleotide - a nucleic acid sequence featuring an enzyme-like activity, such as cleavage, ligation, splicing-out (cleaving both ends of a short nucleic acid sequence to remove it from a longer sequence and ligating the ends of the cut), splcing-in (cleaving open a nucleic acid sequence, inserting another short nucleic acid sequence and ligating the ends of the cut), rearrangement, as well as additional catalytic activities such as phosphorylation, kinase like activity, addition or removal of other chemical moieties, biotinilation, gap filling of missing nucleotides, polymerization, etc.
  • an enzyme-like activity such as cleavage, ligation, splicing-out (cleaving both ends of a short nucleic acid sequence to remove it from a longer sequence and ligating the ends of the cut), splcing-in (cleaving open a nucleic acid sequence
  • Pre-catalytic oligonucleotides - oligonucleotides which are initially inactive but can become catalytically active in the presence of a suitable molecule which serves as their co-factor an example of such oligonucleotides are allosteric ribozymes as featured in U.S. 5,589,332 and WO 98/0897, WO 94/13833.
  • the term is equivalent also to the term "allosteric oligonucleotide" as will be explained below.
  • Co-factor - a molecule or a moiety within a molecule that reverts the pre-catalytic oligonucleotides ("allosteric oligonucleotide”) from their initially inactive form to an active form.
  • This may be a protein, a peptide, a hormone (or a moiety therein), a nucleic acid sequence (mRNA, DNA), a nucleotide, a toxin or any other molecule or moiety from a biological source.
  • mRNA, DNA nucleic acid sequence
  • nucleotide a toxin or any other molecule or moiety from a biological source.
  • it is a cellular or viral protein or mRNA which characterizes a "desired cell population" (see below).
  • Array - a predetermined spatial arrangement of catalytic oligonucleotides, pre-catalytic oligonuceotides or candidates for catalytic oligonucleotides present on a solid support, (see below) or in an array of containers (see below) wherein each oligonucleotide-bearing location (see below) or each container, respectively, holds one oligonucleotide species.
  • Oligonucleotide-bearing location - a specific area in the solid support on which there are held oligonucleotides of the same specie.
  • the solid support may hold several identical such locations, for example, 100 dots all having oligonucleotide specie "X", 100 dots having nucleotide species "Y”, etc.
  • Solid support - a rigid surface which carries the array of catalytic oligonucleotides, pre-catalytic nucleotides or candidates for catalytic oligonucleotides.
  • Array of containers an arrangement of liquid-holding containers, for example, a multi-well arrangement, wherein each container holds a single species of oligonucleotides.
  • Positive selection - a step of in vitro evolutions wherein oligonucleotides which show cataytic activity under a desired condition are selected.
  • Negative selection a step of in vitro evolution wherein oligonucleotides which show catalytic activity under a non-desired condition or which do not show catalytic activity under a desired condition are discarded.
  • Heterologous nucleic acid sequence also referred to at times as “heterologous gene/heterologous coding nucleic acid sequence) - a sequence which has a potential of being expressed to give a "desired product” (see below).
  • the sequence is introduced from the outside into the cell by use of a vector.
  • the sequence may be a sequence from another species, a sequence which is the correct version of a mutated and faulty sequence already present in the cell (which mutated sequence causes production of a mutated protein), or sequence already present in the cell which is introduced to the cell in order to raise its level in the cell.
  • the expression of said heterologous sequence is regulated (turn on or off) by an "allosteric oligonucleotide” (see below).
  • Allosteric oligonucleotide refers in fact to pre-catalytic oligonucleotides, which are initially inactive but become catalytically active in the presence of a suitable molecule which serves as the co-factor.
  • the co-factor of the allosteric oligonucleotide is a cellular or viral protein or mRNA.
  • Desired cell population a specific group of cells in which a detection or therapeutic action is to take place.
  • the population is characterized in that cells of the population contain a co-factor for an allosteric oligonucleotide, while other cell populations (not “desired") do not contain the co-factor.
  • the desired cell population may be a viral infected cell population, cancer cells, cells of a specific tissue or cells of a specific stem cell origin, etc.
  • the present invention concerns an array of catalytic oligonucleotides, pre-catalytic oligonucleotides or candidates for catalytic oligonucleotides immobilized on a solid support, wherein each oligonucleotide-bearing location of the solid support, bears essentially a single species of said oligonucleotides.
  • the array of oligonucleotides may include oligonucleotides which are a priori active, such as state of the art ribozymes (made from rNTP's, nNTP's or a combination of rNTP's and dNTP's) which can feature their catalytic activity once their proper substrate is supplied.
  • the array may include pre-catalytic nucleic acid sequences, i.e. oligonucleotides which are a priori inactive, but have the potential of becoming catalytically active, for example, in the presence, of a co- factor ⁇ "effector" which can be a molecule which presence is to be assayed in a sample.
  • the array may contain a huge number of synthesized oligonucleotides, having a random or semi-random sequences, which oligonucleotides are candidates for evolving into catalytically active oligonucleotides in the various in vitro evolutions techniques.
  • oligonucleotides are candidates for evolving into catalytically active oligonucleotides in the various in vitro evolutions techniques.
  • use is made of the predefined spatial of arrangement of the oligonucleotides in the array wherein all oligonucleotides present in a single location or in a single well are of the same species.
  • the assayed molecule may be the substrate of a trans acting, specific catalytic nucleic acid sequence, or a co-factor of a specific pre-catalytic molecule.
  • a trans acting, specific catalytic nucleic acid sequence, or a co-factor of a specific pre-catalytic molecule may be the substrate of a trans acting, specific catalytic nucleic acid sequence, or a co-factor of a specific pre-catalytic molecule.
  • a proto-nucleozyme with a known co-factor requirement is mutagenized and placed on a chip so as to be increase specificity and give more information about unknown other analyte.
  • the randomized pool of proto-nucleozymes that are received after relatively few rounds of evolution are cloned.
  • the pattern of different proto-nucleozymes to which is seen on the chip would indicate more precisely the analyte which activate and might make it possible to characterize the unknown analytes into various "families " and give general prediction of their structure.
  • the precise location of each synthesized oligonucleotide, which is a candidate for evolving to a nucleic acid sequence having catalytic activity, in the array is known or alternatively it is known which clone produced the candidate sequence. Then by determining which locations bear catalytically active oligonucleotides under a desired condition (positive selection step), it is possible to conclude what was the sequence of oligonucleotides in that location and thus to select only oligonucleotides which are catalytically active under said condition. Alternatively, subsequently or simultaneously, it is possible to determine which locations featured catalytic activity in the presence of a non- desired condition, or which did not exhibit catalytic activity under the desired condition and these locations are not selected (negative selection step).
  • the present invention also concerns an array of catalytic oligonucleotides, pre-catalytic oligonucleotides, or candidates for catalytic oligonucleotides present in an array of liquid-holding containers, wherein each container holds essentially a single species of said oligonucleotides.
  • the array of containers may be for example an array of wells, for example a 96-well arrangement.
  • each well there is present essentially one single species of catalytic oligonucleotide, pre-catalytic oligonucleotides or candidates for catalytic oligonucleotides as explained above, and it is a priori known, what is the sequence present in each well.
  • the detection as explained in “the detection aspect” of the invention or the in vitro evolution as explained in the "in vitro evolution aspect” above can take place, wherein one container is equivalent to one "oligonucleotide bearing location " in the solid support.
  • the term "immobilized” refers hereinafter to any type of binding, both covalent and non-covalent of the oligonucleotides to the solid support as well as to absorption or adsorption of the nucleic acid sequences to the solid support.
  • the binding may be covalent by using active groups such as NH 2 .
  • the binding may also be carried out by using nucleic acid binding proteins, for example DNA binding proteins which have been modified to react with the solid substrate.
  • the nucleic acid binding proteins may be derivated for example by thiols so they can bind to glass.
  • Other binding methods of oligonucleotides are well known in the art.
  • the solid support may be of two types: a “static solid support” and the other “retrievable solid support”.
  • the “static solid support” refers to a solid support wherein once the nucleic acid molecules are immobilized thereon, they essentially remain in that same position indefinitely. This means that each oligonucleotide-bearing location in solid support stays in its own place.
  • the static solid support is mostly used in the “detection aspect of the invention " (see below), but can also be used in the "in vitro evolution aspect of the invention ".
  • retrievable solid support refers to types of solid support wherein nucleotide-bearing locations of the solid support can independently be separated from other nucleotide-bearing locations.
  • solid supports are beads, such as sepharose beads or magnetic particles wherein a specific location of beads can be picked up and transferred to a new surface or to a new vessel for further processing.
  • the "retrievable solid support” is mostly used for the "in vitro evolution aspect of the invention ".
  • each oligonucleotide-bearing location there is immobilized essentially a single species of oligonucleotides.
  • a number of identical oligonucleotide species are immobilized in several different adjacent locations in the array.
  • the fact that there exists a plurality of locations all bearing the same oligonucleotide species enables to carry out various statistic manipulations as will be explained hereinbelow.
  • the array of the present invention may be formed as a "biochip" i.e. an array of biological molecules present in a very small area.
  • the biochip consists of a small glass plate coated with a gel.
  • the array of oligonucleotides may be placed on the gel.
  • the biochip can be analyzed for a detectable signal, for example fluorescence, and the result interpreted as will be explained hereinbelow, wherein each location of oligonucleotides present on the biochip is precisely known.
  • a biochip is - lo ⁇
  • the present invention further concerns an assembly for the detection of a location of catalytic activity in the array of the invention.
  • the assembly comprises the array of the invention, as well as signal producers, which are capable of producing a detectable signal upon the activation (catalytic activity) of the catalytic oligonucleotides.
  • signal producers may be an integral part of the oligonucleotides of the array themselves.
  • the oligonucleotides of the array may comprise a fluorescent moiety which becomes detached upon cleavage or splicing and the location where catalytic activity took place can be detected by lack or decrease of fluorescence emission therefrom.
  • the signal producers means may be molecules independent from the oligonucleotides of the array.
  • the catalytic activity of the oligonucleotides is ligation
  • those oligonucleotides which are catalytically active may ligate to themselves a short sequence being a fluorescent moiety, the short sequence in that case is the "signal producing means ".
  • the assembly comprises the array as well as said label bearing sequence which can be attached by ligation.
  • Labeling can be also by a two-step procedure in which catalytic activity (cleavage, ligation, splicing, phosphorylation) creates a site to which a detectable label can be attached in a subsequent step, (for example, by use of antibodies, by use of complementary sequences bearing labels, etc.).
  • the assembly contains said detectable label as well as elements for its attachment to the oligonucleotides.
  • the detection may be read optically by a fluorescent label, or by a dye producing a color reaction as known in the art or by other techniques known for detection.
  • a fluorescent label or by a dye producing a color reaction as known in the art or by other techniques known for detection.
  • Another possibility is the use of magnetic particles as labels, which can be detected by devices capable of detecting weak magnetic fields.
  • the present invention further concerns a system for the detection of the location of catalytically active oligonucleotide species in an array, comprising the
  • Such a detector where the signal is optical, may be for example a CCD camera attached to an analog-to-digital converter, and to a computer capable of analyzing the signal and indicating specifically in which location a catalytic reaction took place.
  • the label is magnetic
  • the device should be a magnetic- field sensor capable of detecting l o precisely the presence and location of weak magnetic fields.
  • the oligonucleotide species which may be catalytic or pre-catalytic, are used to detect the presence of an assayed molecule (also referred at times as “analyte ”) in a sample.
  • the analyte may be a separate molecule (protein, nucleotide molecule) or a
  • the oligonucleotides of the array may be a priori catalytically active, for example, having trans enzymatic activity, and the assayed molecule (analyte) can then be the substrate on which they are active. In that case, if catalytic activity is cleavage or splicing, the assayed molecule can be
  • the trans activity produces a detectable signal.
  • the catalytic activity is ligation of fluorescent-bearing sequence, there may be no need to label the assayed molecule (analyte) and all that is needed is to provide a label-carrying sequence which may be attached to the substrate by ligation.
  • 2 5 catalytically active molecule may be essentially naturally occurring ribozymes that act in trans, or alter molecules that are tailored, or in vitro evolution evolved sequences, developed so that their substrate is the desired analyte.
  • the oligonucleotides are a priori non-active (i.e. they are pre-catalytic oligonucleotides), and become catalytically
  • proto-nucleozymes such pre-catalytic oligonucleotides which are termed therein "proto-nucleozymes " .
  • proto-nucleotzymes should be of the type that they lack a missing component essential for catalytic activity (such as a segment in their core region, or in their stem region) and hence are inactive.
  • a molecule termed "co-factor" can complete the missing region and thus cause the proto-nucleozyme to become active. Only if the co-factor (being the assayed molecule, i.e.
  • the co-factor i.e., may be any type of molecule, such as a nucleic acid sequence, a protein, a hormone, a drug, a nucleotide, etc., which presence is to be detected in a sample as explained in detail in WO 98/0897.
  • an array of catalytic oligonucleotide or pre-catalytic oligonucleotides can be prepared, wherein each location in the array bears one species of oligonucleoties.
  • the different species of the oligonucleotides may become catalytically active in the presence of different co- factors, for example, different proteins.
  • each species of oligonucleotides may become catalytically active in the presence of different epitopes of the same protein.
  • This manner enables to detect, with a very high specificity, a specific protein since all of its specific epitopes are characterized. Only when a correct combination of different oligonucleotide species (present in a correct combination of locations in the array) show catalytic activity, it indicates that a protein having all the specific epitopes was present in the sample. Such a detection may eliminate false negative results, usually encountered in antibody-based detection assays due to cross-reactivity of antibodies with several proteins which have some common epitopes.
  • the present invention concerns a method for detecting the presence of at least one co-factor in a sample comprising:
  • the array of the invention is used for in vitro evolution of catalytic oligonucleotides.
  • catalytically active oligonucleotides are separated from catalytically inactive oligonucleotides, by separating between immobilized and diffusable oligonucleotides.
  • the supernatants may contain oligonucleotides which have undegone catalytic activity, for example, oligonucleotides which are freed from an immobilized solid support by auto-catalytic cleavage. Thus by collecting only the supernatant only catalytically active oligonucletides are collected.
  • the supernatant may hold oligonucleotides which are not catalytically active, for example, oligonucleotides which did not become immobilized, through ligation, to the solid support.
  • the catalytically active oligonucleotides may be obtained in a positive selection step,
  • oligonucleotides In accordance with the in vitro evolution embodiment of the present invention, it is possible to produce an array of candidates for catalytic oligonucleotides, then expose said candidates to a specific selective condition (which may be a desired or non-desired selective condition), and then select, (by one of the two manners disclosed hereinbelow) only oligonucleotide-bearing locations which hold oligonucleotides that have undergone catalytic activity under said condition. Said oligonucleotides may be obtained for the positive selection step, (if the conditions to which the array is subjected is desired) or discarded in a negative selection step (if the condition to which the array is subjected is not desired).
  • a specific selective condition which may be a desired or non-desired selective condition
  • obtaining or discarding the selected oligonucletoides is done physically, i.e. by collecting from a retrievable support only the locations of catalytically active oligonucleotides.
  • an array of a plurality of different oligonucleotide species which are candidates for evolving to catalytic oligonucleotides having a desired catalytic activity under a specific condition, are prepared, and subjected to a specific condition under which they should feature the catalytic activity.
  • the condition may be the presence of a co-factor, a specific temperature, a specific pH, ionic strength, etc.
  • the oligonucleotids are allowed to undergo catalytic activity. Those locations of the array bearing oligonucleotides which underwent catalytic activity are identified by using the assembly of the invention, leading to production of a detactable signal, and the system of the invention reading said signal as described above.
  • those locations bearing said catalytically active species are retrieved, for example, by collecting the sepharose beads, or magnetic particles on which the oligonucleotides are immobilized.
  • the sequences are separated from the obtained locations and are transferred to a nucleic acid analyzer for determining the sequence of the oligonucleotides.
  • the oligonucleotides may be processed for reconstruction in order to revert the oligonucleotides which underwent auto-catalytic activity back to the sequence of original catalytic oligonucleotides prior to auto-catalytic activity. Where the catalytic activity is cleavage said reconstruction may be for example by reconstructing the cleaved sequence.
  • the oligonucleotides are transferred to a new solid substrate, in order to create a new array containing only the selected oligonucleotides. Then, the new array can be subjected again to a specific condition, which may be again a positive selection step albeit under stricter criteria (higher temperature, lower concentration of co-factor, etc.) or a negative selection step. Again, only desired locations are collected, processed for reconstruction, so that the sequence that was changed due to auto-catalytic activity is produced again, and transferred to create a new array.
  • a specific condition which may be again a positive selection step albeit under stricter criteria (higher temperature, lower concentration of co-factor, etc.) or a negative selection step.
  • separation between catalytically active and catalytically inactive oligonucleotides may be carried out without separation of the supernatants and the immobilized portions in the reaction vessel, but rather simply by physically picking up those locations which are desired, i.e. locations which are labeled.
  • oligonucleotides having a desired activity for example, catalytic activity in the presence of a specific co-factor; catalytic activity in the presence of a specific temperature, etc.
  • a desired activity for example, catalytic activity in the presence of a specific co-factor; catalytic activity in the presence of a specific temperature, etc.
  • sequences of those active oligonucleotides may be determined, for example, by automatic nucleic acid sequencer.
  • these selected sequences may be synthesized again for mass production, or the clones producing these sequences can be identified and used for mass production.
  • the selected sequences may be synthesized again (either separately and then deposited or in situ on the solid support) in order to create a new array having only oligonucleotides which have shown a specific catalytic activity under a desired condition.
  • the new array may again be subjected either to a second selective condition, or to the first condition under more strict criteria, and again, by using the computer's memory, it is possible to know what is the sequence of the oligonucleotide positioned on those locations which showed a detectable signal indicating catalytic activity.
  • each location bears a sequence having a computer stored sequence
  • oligonucleotides are amplified utilizing enzyme-based amplification methods such as PCR.
  • enzyme-based amplification methods such as PCR.
  • PCR enzyme-based amplification methods
  • sequences which contain, or are composed of, non-naturally occurring nucleotides such as O-methyl nucleotides. Then each species of sequences is placed in a single location and the sequence of each location is known (stored in the computer's memory).
  • a plurality of identical arrays of the invention is used, wherein in each location of the identical arrays, there is present essentially a single species of oligonucleotides which are candidates for catalytic activity.
  • the plurality of the arrays are exposed to a desired selection condition.
  • a "cut-off percentage" is set. For example, if a specific location showed catalytic activity under the selected condition in at least 90% of the arrays, then the specific location is defined as one carrying catalytically active oligonucleotides which should be obtained. Alternatively, or in addition, a corresponding plurality of arrays is exposed to a non-desired condition, i.e. a condition wherein no catalytic activity should take place. Again a "cut-off percentage " is selected, for example, 1%. Only these locations which showed catalytic activity of less than 1% of the arrays (i.e. less than 1%), under the non-desired condition, and 90% catalytic activity under the desired condition are chosen. Alternatively, it is possible to simply choose the best location (which had the highest activity under a desired condition and the lowest activity under a non-desired condition), without, a priori, defining "cut-off" levels.
  • the selective conditions are initially quite permissive but they become more stringent as selection cycles proceed.
  • it is preferable to start the selection process by first exposing the oligonucleotides to the most stringent conditions desired. For example, where it is desired to select for oligonucleotides which are catalytically active only in the presence of a specific co- factor, it is preferable to first expose the plurality of the arrays to the lowest concentration of co-factors desired. If no catalytic activity is detected in none of the locations, then the concentration can gradually rise, until a concentration is reached wherein a minimal detectable signal is produced. Another example is to choose catalytic oligonucleotides which are active in the lowest temperature possible. Again, it is possible to expose nucleotides to a very low temperature and if no catalytic activity is evident, slowly raise the catalytic activity.
  • the present invention concerns a method for in vivo or in situ determination of an analyte (or assayed molecule) in cells.
  • the analyte can be any compound whose presence is to be detected inside cells, such as a protein, a metabolite, a hormone, a drug, a nucleoside, molecule from an infectious agent, etc.
  • pre-catalytic oligonucleotides of the type that the analyte serves as a co-factor for its catalytic activity according to the teaching of WO 98/08974 are prepared, in such a manner that its auto-catalytic activity changes a detectable property in the oligonucleotide.
  • the pre-catalytic oligonucleotide may comprise a fluorescent label, as well as a moiety capable of quenching fluorescence. If the fluorescent label and the quencher are adjacent to each other, the fluorescence is quenched, and essentially there is no fluorescent emission. However, in the presence of an appropriate co-factor, the pre-catalytic oligonucleotide becomes catalytic, and cleaves the fluorescent label, which by diffusion is distanced from the quencher so its fluorescence radiation is evident.
  • Detection of fluorescence indicates the presence of a catalytic activity of the oligonucleotide, which in turn indicates the presence of the analyte which served as the co-factor of the pre-catalytic oligonucleotide.
  • This construct is present inside a vector capable of entering cells, such as a plasmid, a suitable viral vector, etc.
  • the pre-catalytic nucleic acid sequence can become catalytically active if the analyte is present inside the cell.
  • the label will be distanced from the quencher, and the cell will show fluorescence, which fluorescence may be dete ⁇ nined by any manner known in the art.
  • the present invention concerns an insertion vector for inserting at least one nucleic acid construct into a cell; the construct comprising a protonucleozyme being a nucleic acid molecule or complex of nucleic acid molecules having essentially no catalytic activity but can complex with a co-factor to form a nucleozyme which possess catalytic activity, the protonucleozyme lacks a component essential for the catalytic activity of the nucleozyme and said co-factor provides said component; the nucleic acid construct comprising to a detectable moiety which changes at least one detectable property upon cis catalytic activity of the nucleozyme, the co-factor of the protonucleozyme being a molecule or a moiety within a molecule found in cells.
  • the present invention further concerns a method for determining the presence of an analyte in vivo or in situ, a cell comprising:
  • the method and construct of the invention are suitable for dete ⁇ nining, or monitoring the presence of a single analyte (protein, metabolite, hormone drug, toxic substance, etc.) in the cells in vivo, or in situ, and may be used in cases where it is desired to "view " the inside of the cell, for example, to monitor the spread of a viral infection, the penetration of a pharmaceutical agent, etc.
  • the method, and the construct may be used to dete ⁇ nine, or monitor a plurality of different analytes in the cell simultaneously.
  • the vector will contain a plurality of pre-catalytic sequences, each one capable of being activated by a different analyte which serves as its specific co- factor.
  • each cleaved part of the substrate carries also a tag sequence enabling its identification.
  • the tag may be an immunogenic moiety, capable of being recognized by specific antibodies.
  • the tag sequence which identifies the type of the pre-catalytic nucleic acid attached thereto (and by this identified which analyte served as a specific co- factor for this pre-catalytic sequence) is a nucleic acid sequence.
  • the tag sequence can be detected by breaking up cells, so that their contents are released to the medium. Then, the contents of the released cells are brought into contact with an oligonucleotide chip, containing sequences complementary to said tag sequences.
  • an oligonucleotide chip containing sequences complementary to said tag sequences.
  • the present invention concerns a vector as described above comprising a plurality of nucleic acid constructs, each construct comprising a protonucleozyme which becomes catalytically active through complexing with a different co-factor, each nucleic acid construct further comprising an identification tag sequence, said identical tag sequence being adjacent to the detectable label, and being detached, together with said label, from the construct through catalytic activity.
  • the invention further concerns a method for the simultaneous dete ⁇ nination of a plurality of analytes in vivo or in situ in a cell, the method comprising:
  • the present invention concerns a method for the control of expression of a heterologously induced nucleic acid coding sequence.
  • heterologously induced nucleic acid sequence refers to a nucleic acid sequence, which is induced to the cell from an external source, and has a potential of becoming expressed to give a desired product.
  • heterologous should be understood to refer both to a sequence coding for a protein which the cell originally does not have at all (for example from another species), a sequence which has a mutated counte ⁇ art in the cell, and a correct sequence is heterologously introduced (for example to compensate for lack of metabolite) as well as a sequence which is already present in the cell, and it is desired to increase the level of mRNA of said sequence.
  • said heterologous sequence is placed in a nucleic acid construct, in such a manner that, only upon activity of a catalytic nucleic acid sequence it can either revert from non-expression to expression (up-regulated) or from expression to non-expression (down-regulated).
  • non expression refers to the fact that the sequence produces the desired product (protein or mRNA). Production of non-desired products (for example, fragments of the full protein) or non-production of all are collectively referred to as “non expression ".
  • the heterologous nucleic acid sequence may be broken into two parts with an intervening sequence thereinbetween. Only splicing out of this intervening sequence will enable expression of the sequence to produce the desired product (without said splicing only a short fragment is produced).
  • the intervening sequence may be a substrate for splicing activity of a catalytic nucleic acid sequence in trans, or alternatively, may be the catalytic nucleic acid sequence itself, which by cis - auto catalytic splicing, excising itself out of the heterologous sequence and ligating the two open ends thus enabling production of the desired product.
  • the heterologous nucleic acid sequence may, a priori, comprise an inhibitory control sequence. Only cleaving or splicing out of this inhibitory sequence causes the catalytic nucleic acid sequence to be expressed.
  • An example of down-regulation is a heterologous nucleic acid sequence that, a priori, is expressed to give the desired product. Only upon catalytic activity, such as cleaving or splicing, its expression is terminated, for example, due to cleaving of a promoter, or due to the fact that cleaving cutting the sequence to give non-desired short fragments.
  • the catalytic oligonucleotide sequence should be of the allosteric type, i.e.
  • a preferred embodiment is the proto-nucleozymes specified in WO 98/08975 which lacks a component essential for its catalytic activity and said co-factor completes said component.
  • the co-factor is a molecule or moiety within a molecule which is present essentially only in the desired cell population and is not present in other cell populations.
  • the allosteric oligonucleotide become active, in turn regulating (up- or down-regulation) the expression of the heterologous sequence.
  • the heterologous nucleic acid sequence is intended to produce a detectable label for diagnostic pu ⁇ oses.
  • the heterologous sequence may be the luciferase gene which, when expressed, produces a luciferase enzyme capable of providing bioluminescence.
  • the luciferase gene is introduced into the cell with an allosteric oligonucleotide present in such a manner which it cannot be expressed (for example the allosteric oligonucleotide interrupts coding sequence) then only if the correct co-factor of the allosteric oligonucleotide is present, then the catalytic sequence becomes active, splices itself out of the luciferase gene sequence, thus enabling production of bioluminescence.
  • the co-factor is for example an analyte to be detected inside cells, such as a viral protein
  • bioluminescence can be indicative of the presence of the viral protein within the cells. This fact may be used in screening for drugs wherein it is desired to detect those cells which respond to the drug by change of a cellular component which is the co-factor.
  • the heterologous sequence may be a sequence of a gene used in gene therapy for therapeutic pu ⁇ oses.
  • the allosteric oligonucleotide can be used to turn on or off production of a therapeutic product
  • heterologous gene being controlled so as to be expressed only in a specific sub-set of cells (being the desired cell population).
  • the heterologous gene is a cytotoxic gene such as a gene coding for a toxin or caspase
  • cytotoxic gene expression is regulated by an allosteric oligonucleotide
  • cell death by expression of the cytotoxic sequence can be regulated, so that only viral infected or cancerous cells, which produce the co-factor required for the activity of the allosteric oligonucleotides are destroyed, while cells not comprising said co-factor are not destroyed.
  • the heterologous sequence used for therapeutic pu ⁇ oses can be sequences coding for cytotoxic agents or any other sequence which expression has a beneficial effect in cells.
  • aberrant mRNA production leading to aberrant protein production
  • the aberrant mRNA or the aberrant protein is used as the co-factor of the allosteric oligonucleotide, and the heterologous gene which is regulated by the allosteric oligonucleotide is the correct sequence, then the aberrant mRNA (or the aberrant protein) causes production of the correct mRNA or protein only in cells where the defective gene is expressed.
  • a therapeutic agent is for providing a necessary product only in a certain type of cell (for example cells originating from white blood cells stem line which do not produce a specific enzyme), and in such a case the co- factor is any type of protein which characterizes these cells.
  • the present invention further provides an insertion vector for inserting at least one nucleic acid construct into a cell the construct comprising a heterologous coding nucleic acid sequence and an allosteric oligonucleotide which allosteric oligonucleotide has essentially no catalytic activity in the construct but can complex with a co-factor to become catalytically active; catalytic activity of the allosteric oligonucleotide regulating the expression of the heterologous coding nucleic cid sequence; wherein said co- factor is a molecule or a moiety within a molecule found inside cells.
  • the allosteric oligonucleotide comprises an allosteric oligonucleotide which is a priori inactive but which becomes active in the presence of a specific co-factor protonucleozyme being a nucleic acid molecule or complex of nucleic acid molecules having essentially no catalytic activity but can complex with a co-factor to form a nucleozyme which possess catalytic activity, the protonucleozyme lacking a component essential for the catalytic activity of the nucleozyme and said co-factor provides said component.
  • a specific co-factor protonucleozyme being a nucleic acid molecule or complex of nucleic acid molecules having essentially no catalytic activity but can complex with a co-factor to form a nucleozyme which possess catalytic activity, the protonucleozyme lacking a component essential for the catalytic activity of the nucleozyme and said co-factor provides said component.
  • Fig. 1 is a schematic representation of an array of pre-catalytic oligonucleotides on a solid support used for detection
  • Fig. 2 is a schematic representation of an array of pre-catalytic oligonucleotides present in an array of liquid-holding containers used for detection
  • Figs. 3A, 3B and 3C are a schematic representation of an array of candidates for catalytic oligonucleotides present in an array of containers used for in vitro evolution, wherein each step of the method selected conditions become more stringent;
  • Fig. 4 is a schematic representation of a plurality of arrays of candidates for catalytic oligonculeotides present on a plurality of solid supports used for in vitro evolution;
  • Figs. 5A-F show a schematic representation of the method for determining or monitoring in vivo or in situ analytes in cells.
  • Fig. 6A shows a method for regulating heterologous expression by allosteric nucleic acid sequences for detection pu ⁇ oses
  • Fig. 6B shows a method as a GA used for therapeutic pu ⁇ oses
  • Fig. 7 shows a gel analysis proving splicing of a protonucleozyme in the presence of a target.
  • Fig. 1 shows an array of the invention 1 present on a solid support 2, which is a glass slide covered with nucleic acid holding gel. On said gel, there are deposited in a predefined manner, thirty locations of 30 different species of pre-catalytic oligonucleotides 3, arranged in five columns (1 to 5) and eight rows A to F.
  • each of locations 3 there is deposited, a specific and known sequence of pre-catalytic oligonucleotides.
  • These pre-catalytic oligonucleotides are of the type which have a missing region, missing from their core or stem, that is completed by an epitope of a specific protein, or by a specific nucleic acid sequence which is to be assayed as defined in WO 98/08974.
  • All five locations of each row for example locations 1, 2, 3, 4 and 5 of row A are deposited with five pre-catalytic species which become catalytically active in the presence of five different epitopes of the same protein or nucleic acid sequence. Thus, only if all of five locations 1 to 5 of a specific row are catalytically active, this indicates that the specific protein or nucleic acid sequence is present in the sample.
  • the array was incubated with a sample, which is to be assayed simultaneously for the presence of six different proteins A to F.
  • the pre-catalytic oligonucleotides were a priori catalytically inactive.
  • Each oligonucleotide contains a substrate for auto-catalytic activity of ligation of a fluorescent being labeled thereto. Fluorescent label is schematically indicated in the figure by a dark shade.
  • the array was incubated with the sample under conditions enabling catalytic activity, and incubation takes place in the presence of a label, which is a fluorescent-bearing short sequence of oligonucleotides which can be ligated only to oligonucleotides which have become catalytic, i.e. only with those oligonucleotides which their co- factor was present in the sample. Then the array was thoroughly rinsed to remove unattached fluorescent label.
  • a label which is a fluorescent-bearing short sequence of oligonucleotides which can be ligated only to oligonucleotides which have become catalytic, i.e. only with those oligonucleotides which their co- factor was present in the sample.
  • proteins C and E As can be seen, in the sample were present proteins C and E, as all five epitopes 1 to 5 of each of these proteins showed a fluorescent label. In addition, there was present a protein, which shared some epitopes (epitopes 2 and 4) with protein A. However, since not all of the locations of the five epitopes of protein A were labeled, this means that protein A itself was not present in the sample, but only proteins having some shared epitopes.
  • the results may be read manually, or alternatively may be read by a CCD camera, which is connected (via an analog-to digital converter) to a computer which can give quickly a "yes/no " answer only if all five epitopes of the protein were present.
  • Fig. 2 shows an array of containers 20.
  • the array is a multi-well device 21, containing thirty wells 22, each well holding a liquid in which there is present one species of pre-catalytic oligonucleotides 23.
  • the wells are arranged in columns 1 to 5 and rows A to F, as explained for Fig. 1, and each well, in fact holds exactly the same oligonucleotide species as the corresponding location in the solid support of Fig. 1.
  • the analysis of the results is the same as described above in Fig. 1.
  • Fig. 3 shows a schematic representation of the in vitro evolution aspect of the invention.
  • step (I) of the method (Fig. 3A) an array of fifteen containers is prepared, each one holding one species of synthetically produced oligonucleotides, which serve as candidates for a catalytic oligonucleotide.
  • the oligonucleotides all show a common conserved sequence, derived from a state-of-the-art ribozymes and have also a random or semi-random variable sequence (semi-random means a sequence which showed a certain similarity, for example 70%> similarity with a known sequence and is usually prepared by a technique termed "dopping"). It is, for example, desired to select for oligonucleotides which have catalytic activity at a temperature of 4°C.
  • the candidate for catalytic oligonucleotides are placed in room temperature at 20°C, and it is determined in which containers catalytic activity, for example ligation with a fluorescent label is evident, as for example, can be identified by fluoresence labeling (represented schematically by a dark shade).
  • these containers are Al, A3, A4, Bl, B2, B3, C2, C3 and C5.
  • step (II) Fig. 3B
  • This nine container new array is then subjected to a temperature of 10°C and it is dete ⁇ nined which oligonucleotides in which containers have catalytic activity in this temperature.
  • it is container a(I), b(II), b(III) and c(I) and c(II).
  • step (III) (Fig. 3C) is then subjected to a temperature of 4°C and it is clearly shown that only containers 20 and 40 hold the desired oligonucleotides having catalytic activity at this temperature. Then, the sequence of oligonucleotides 20 and 40 may be determined, by a nucleic acid sequence and they may be mass produced.
  • the in vitro evolution method is represented, for convenience means as carried out by use of an array of containers.
  • an array of oligonucleotides present on a solid support is the practical choice.
  • the computer stores in its memory, the sequence of each oligonucleotide present in each one of the fifteen locations A1-A5, B1-B5, C1-C5 in the original array (I). Then, after the computer determines that only the specific nine locations Al, A3, A4, Bl, B2, B3, C2, C3 and C5 show catalytic activity, a nucleic acid synthesizer can automatically creates a new array (II), having only these nine species of oligonucleotides.
  • the computer can read in which locations catalytic activity took place, and since it stores in its memory what is the sequence of each location, the nucleic acid synthesizer it can again prepare only these oligonucleotides in order to prepare the third array (III).
  • the oligonucleotides may be created by the computer separately, i.e. not on the chip and then deposited on the chip using a computer-controlled robot.
  • the oligonucleotides may be synthesized in a computerized-controlled manner, in situ on the solid support itself.
  • the sequences in each location may be obtained from a single clone prepared by genetic engineering methods. The computer has to store from which clone the sequences of each location were obtained, rather than the sequence themselves. Later, after several selective cycles, the clone may be used for mass production of the sequence.
  • FIG. 4 shows another embodiment in accordance with the in vitro evolution aspect of the present invention.
  • a plurality of identical arrays of oligonucleotide, candidates for catalytic activity are prepared, for example, in the present drawing 20 such identical arrays.
  • the arrays hold oligonucleotides which are candidates for catalytic activity (which is ligation with a fluorescent bearing sequence) immobilized in a gel on a glass plate.
  • each array holds fifteen different locations, bearing fifteen different species of candidate oligonucleotides. All oligonucleotides share a common conserved sequence, as well as a random or semi-random sequence which is to be selected.
  • each array is in fact a biochip which holds 10,000-1,000,000 different species, and a plurality of arrays, for example a 100 or 1,000 which numbers are all identical if prepared.
  • Half of the arrays are exposed to a desired selection consisting for example the presence of the protein bovine serum albumin BSA (i.e. a catalytic activity should be evident in the presence of this molecule which serves as a co-factor).
  • BSA protein bovine serum albumin
  • the other half of the arrays is exposed to lack of the desired condition, i.e. catalytic activity should not be present in the absence of BSA.
  • a " cut-off percentage " criteria is set both for the positive selection step (present BSA) and negative selection (absence of BSA).
  • the positive criteria is that at least 80% of the locations are active in the presence of BSA, and not more than 10% of the locations are active in the absence of BSA.
  • Table 1 The results are summarized in Table 1 shown below. Table 1
  • position C2 fulfills the above cut-off criteria, as more than 80% of the array should be active in the presence of BSA, and no more than 10% of the arrays should be active in the absence of BSA.
  • the selection criteria are gradually made more stringent with each round of selection. For example, where the desired activity is the presence of a certain compound such as BSA, then in each round of selection the concentration of the BSA is lowered. This is done since it is very difficult to discriminate in the beginning between "noise " and "signal " so that in order not to lose the signal, the criteria is initially quite liberal, and only when some noise is eliminated, then the criteria may be made more stringent.
  • oligonucleotides which show catalytic activity in the presence of two selective conditions, either by exposing the arrays to the two conditions at once, or by using for example four or five duplicate sets of arrays, and then selecting locations which are active above a "cut-off percentage " in all the selected conditions and are active in less than a cut-off percentage in all non-selected conditions.
  • Fig. 5 shows the method for determining, or monitoring in situ or in vivo analytes inside cells.
  • Fig. 5A shows the pre-catalytic oligonucleotide 1.
  • the oligonucleotide has an analyte binding region 2, which can bind the analyte to be detected, for example, a certain protein produced by viruses which indicates the cell is infected by said virus.
  • the oligonucleotide 1 has a sequence 3, which serves as a substrate for cleavage.
  • the oligonucleotide carries two moieties which enable detection, the first moiety 4 is a fluorescent label such as fluorescein.
  • the second is a wavelength modulator 5.
  • modulator 5 and fluorescent label 4 are adjacent to each other, such as shown in Fig. 5 A, the wavelength fluorescence of 4 is shifted, and if the fluorescent rendered is set to the unshifted wavelength no signal is detected.
  • the oligonucleotide carries identification tag sequence 6.
  • a construct for inserting the oligonucleotides 1 into cell 7 (Fig. 5B) is prepared.
  • the construct may be a plasmid, a carrier viral vector, etc.
  • analyte 8 for example a viral protein
  • the pre-catalytic oligonucleotide converts to its catalytically active form due to binding of analyte 8 (Fig. 5D).
  • the medium molecule 9 comprising the fluorescent label 4 and identification tag sequence 6 (Fig. 5E)
  • Such a method enables real-time monitoring in live tissue of analytes.
  • the oligonucleotide 1 does not have to carry an identification tag sequence, which is to be used only where a plurality of analytes are to be detected simultaneously.
  • the construct for inserting the oligonucleotides into the cells carries a plurality of different oliognucletoides 1, each having a slightly different analyte-binding region 2, which can be activated by different analytes.
  • Fig. 5F shows an embodiment of the detection or determination assay used to detect a plurality of different analytes simultaneously.
  • the construct for inserting the oligonucleotides into the cells (being a plasmid, viral vector, etc.) carries a plurality of different oligonucleotides each one having a slightly different analyte-binding region 2 which can be activated by different analytes
  • the figure shows a chip 10 having schematically three short sequences thereon 11, 12 and 13 each complementary to a different identification tag sequence of the original pre-catalytic oligonucleotides 1.
  • Molecules 14 and 15 are short sequences cleaved from oligonucleotides
  • Oligonucleotide 16 which bind to complementary sequence 13 has a wavelength due to the modulator moiety being adjacent to the fluorescent label so that if the fluorescent reader is set to a specific wavelength no fluorescent is read.
  • FIG. 6A shows the aspect of regulating the expression of a heterologous gene, for detection pu ⁇ oses.
  • a nucleic acid construct top representation is built comprising a gene coding for a detectable - 37-
  • the allostric oligonucleotide in the present case is of the type of protonucleozyme as specified in WO 98/08974 which has a missing component which can be completed by a suitable co-factor.
  • the construct is inserted (for example by a vector) into cells (second representation. The insertion is indiscriminate, i.e. all cells may contain this construct).
  • the co-factor is, for example, a viral protein present only in cells infected with the virus.
  • the heterologous nucleic acid sequence is one coding for a therapeutical agent (marked schematically as Vi ⁇ ).
  • this agent may be a toxin or a cytotoxic agent such as catapase.
  • the allosteric oligonucleotide is spliced out, and the cytotoxic gene may be expressed producing the product (t) leading to death only of these cells.
  • Fig. 7 shows the results of splicing catalytic activity obtained by a protonucleozyme capable of self-splicing only in the presence of a specific co- factor.
  • a series of protonucleozymes derived from a variety of Group I intron ribozymes (referred to in Table 2 below) were engineered. The protonucleozymes hybridize to a specific co-factor resulting in an active ribozyme (nucleozyme). Its activity resulted on the excision followed by the ligation of its 5' and 3' exons, (i.e. splicing). Radioactively labeled GTP (needed for the reaction to proceed) was used to follow the activity of the constructs. The GTP binds to the resulting intron (see Fig. 7) producing a size shift that is detected on gel electrophoresis (Fig. 7).
  • Controls were carried out in the absence of co-factor for each one of the specific pronucleozyme. 1 5 The reactions were stopped by the addition of 2x loading buffer in the presence of 7M urea, heated at 80°C for 5 minutes and run on 20% AGE in the prsence of 7M urea.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un arrangement de séquences nucléotidiques catalytiques ou de séquences présentant un potentiel catalytique, répondant une disposition spatiale prédéterminée. On peut utiliser cet arrangement à des fins de détection et de transformation in vitro.
PCT/IL2000/000370 1999-06-23 2000-06-23 Arrangements de sequences nucleotidiques WO2001000869A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00939029A EP1194573A2 (fr) 1999-06-23 2000-06-23 Arrangements nucleotidiques catalytiques ou pre-catalytiques
JP2001506860A JP2003503068A (ja) 1999-06-23 2000-06-23 核酸配列のアレイ
AU54238/00A AU5423800A (en) 1999-06-23 2000-06-23 Arrays of nucleic acid sequences

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13060699A IL130606A0 (en) 1999-06-23 1999-06-23 An array of nucleic acid sequence
IL130606 1999-06-23

Publications (2)

Publication Number Publication Date
WO2001000869A2 true WO2001000869A2 (fr) 2001-01-04
WO2001000869A3 WO2001000869A3 (fr) 2001-05-10

Family

ID=11072952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2000/000370 WO2001000869A2 (fr) 1999-06-23 2000-06-23 Arrangements de sequences nucleotidiques

Country Status (5)

Country Link
EP (1) EP1194573A2 (fr)
JP (1) JP2003503068A (fr)
AU (1) AU5423800A (fr)
IL (1) IL130606A0 (fr)
WO (1) WO2001000869A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506887B1 (en) 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
US7871822B2 (en) * 2004-01-30 2011-01-18 Novalyst Discovery Method of use for characterizing the catalytic reactivity of catalyst(s)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013791A1 (fr) * 1992-12-04 1994-06-23 Innovir Laboratories, Inc. Acide nucleique regulable a usage therapeutique et procedes d'utilisation associes
WO1994013833A1 (fr) * 1992-12-04 1994-06-23 Innovir Laboratories, Inc. Diagnostic resultant de l'amplification du signal de reaction produit par une ribozyme
WO1994029481A1 (fr) * 1993-06-03 1994-12-22 Asher Nathan Detection de sequences d'acides nucleiques
DE4424762C1 (de) * 1994-07-04 1995-07-27 Max Planck Gesellschaft Ribozym-Bibliothek, ihre Herstellung und ihre Verwendung
WO1996027026A1 (fr) * 1995-02-27 1996-09-06 Intelligene Ltd. Detection de biomolecules
WO1997019749A1 (fr) * 1995-11-27 1997-06-05 Dehlinger Peter J Procede et appareil de production de bibliotheques combinatoires adressables par positions
WO1998008974A2 (fr) * 1996-08-26 1998-03-05 Intelligene Ltd. Acide nucleique catalytique et son utilisation en medecine
WO1998027104A1 (fr) * 1996-12-19 1998-06-25 Yale University Polynucleotides allosteres bioreactifs
WO1998032880A1 (fr) * 1997-01-23 1998-07-30 Immusol Incorporated Analyse fonctionnelle et decouverte de genes a l'aide de banques de vecteurs de genes de ribozymes specifiques a une cible ou bien rendues aleatoires
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
WO1999027140A1 (fr) * 1997-11-26 1999-06-03 Lockheed Martin Energy Research Corporation Microsysteme sous forme de biopuce a circuit integre
WO1999047704A1 (fr) * 1998-03-17 1999-09-23 Andreas Jenne Composition contenant un adn codant pour un ribozyme et un substrat oligonucleotidique, et technique permettant de mesurer la vitesse de transcription
WO2000024931A2 (fr) * 1998-10-23 2000-05-04 Intelligene Ltd. Detection d'analytes
WO2000026226A1 (fr) * 1998-11-03 2000-05-11 Yale University Detecteurs moleculaires polynucleotidiques a domaines multiples

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013791A1 (fr) * 1992-12-04 1994-06-23 Innovir Laboratories, Inc. Acide nucleique regulable a usage therapeutique et procedes d'utilisation associes
WO1994013833A1 (fr) * 1992-12-04 1994-06-23 Innovir Laboratories, Inc. Diagnostic resultant de l'amplification du signal de reaction produit par une ribozyme
WO1994029481A1 (fr) * 1993-06-03 1994-12-22 Asher Nathan Detection de sequences d'acides nucleiques
DE4424762C1 (de) * 1994-07-04 1995-07-27 Max Planck Gesellschaft Ribozym-Bibliothek, ihre Herstellung und ihre Verwendung
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
WO1996027026A1 (fr) * 1995-02-27 1996-09-06 Intelligene Ltd. Detection de biomolecules
WO1997019749A1 (fr) * 1995-11-27 1997-06-05 Dehlinger Peter J Procede et appareil de production de bibliotheques combinatoires adressables par positions
WO1998008974A2 (fr) * 1996-08-26 1998-03-05 Intelligene Ltd. Acide nucleique catalytique et son utilisation en medecine
WO1998027104A1 (fr) * 1996-12-19 1998-06-25 Yale University Polynucleotides allosteres bioreactifs
WO1998032880A1 (fr) * 1997-01-23 1998-07-30 Immusol Incorporated Analyse fonctionnelle et decouverte de genes a l'aide de banques de vecteurs de genes de ribozymes specifiques a une cible ou bien rendues aleatoires
WO1999027140A1 (fr) * 1997-11-26 1999-06-03 Lockheed Martin Energy Research Corporation Microsysteme sous forme de biopuce a circuit integre
WO1999047704A1 (fr) * 1998-03-17 1999-09-23 Andreas Jenne Composition contenant un adn codant pour un ribozyme et un substrat oligonucleotidique, et technique permettant de mesurer la vitesse de transcription
WO2000024931A2 (fr) * 1998-10-23 2000-05-04 Intelligene Ltd. Detection d'analytes
WO2000026226A1 (fr) * 1998-11-03 2000-05-11 Yale University Detecteurs moleculaires polynucleotidiques a domaines multiples

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BARTEL D P ET AL: "ISOLATION OF NEW RIBOZYMES FROM A LARGE POOL OF RANDOM SEQUENCES" SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 261, no. 5127, 10 September 1993 (1993-09-10), pages 1411-1418, XP000563737 ISSN: 0036-8075 *
BRAMLAGE B ET AL: "Designing ribozymes for the inhibition of gene expression" TRENDS IN BIOTECHNOLOGY,GB,ELSEVIER PUBLICATIONS, CAMBRIDGE, vol. 16, no. 10, 1 October 1998 (1998-10-01), pages 434-438, XP004145651 ISSN: 0167-7799 *
FUJITA S ET AL: "DISCRIMINATION OF A SINGLE BASE CHANGE IN A RIBOZYME USING THE GENEFOR DIHYDROFOLATE REDUCTASE AS A SELCTIVE MARKER IN ESCHERICHIA COLI" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 94, January 1997 (1997-01), pages 391-396, XP000700235 ISSN: 0027-8424 *
HANNE A ET AL: "FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) TO FOLLOW RIBOZYME REACTIONS IN REAL TIME" NUCLEOSIDES & NUCLEOTIDES,US,MARCEL DEKKER, INC, vol. 17, no. 9-11, 1998, pages 1835-1850, XP000891507 ISSN: 0732-8311 *
KOSEKI S ET AL: "A simple assay system for examination of the inhibitory potential in vivo of decoy RNAs, ribozymes and other drugs by measuring the Tat-mediated transcription of a fusion gene composed of the long terminal repeat of HIV-1 and a gene for luciferase" JOURNAL OF CONTROLLED RELEASE,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM,NL, vol. 53, no. 1-3, 30 April 1998 (1998-04-30), pages 159-173, XP004121267 ISSN: 0168-3659 *
ROBERTSON D L ET AL: "SELECTION IN VITRO OF A RNA ENZYME THAT SPECIFICALLY CLEAVES SINGLE-STRANDED DNA" NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 344, 29 March 1990 (1990-03-29), pages 467-468, XP000673537 ISSN: 0028-0836 *
ROBERTSON M P ET AL: "IN VITRO SELECTION OF AN ALLOSTERIC RIBOZYME THAT TRANSDUCES ANALYTES TO AMPLICONS" NATURE BIOTECHNOLOGY,US,NATURE PUBLISHING, vol. 17, no. 1, January 1999 (1999-01), pages 62-66, XP000914846 ISSN: 1087-0156 *
SOUKUP GARRETT A ET AL: "Engineering precision RNA molecular switches." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 7, 30 March 1999 (1999-03-30), pages 3584-3589, XP002158536 March 30, 1999 ISSN: 0027-8424 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506887B1 (en) 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
US6706482B2 (en) 1999-07-29 2004-03-16 Somalogic, Inc. Conditional-selex
US7871822B2 (en) * 2004-01-30 2011-01-18 Novalyst Discovery Method of use for characterizing the catalytic reactivity of catalyst(s)

Also Published As

Publication number Publication date
JP2003503068A (ja) 2003-01-28
IL130606A0 (en) 2000-06-01
AU5423800A (en) 2001-01-31
EP1194573A2 (fr) 2002-04-10
WO2001000869A3 (fr) 2001-05-10

Similar Documents

Publication Publication Date Title
EP0743989B1 (fr) Procédé d'identifcation des genes exprimés differentes
US6232067B1 (en) Adapter directed expression analysis
US7919239B2 (en) Increasing hybridization efficiencies
CN116829733A (zh) 用于将分析物结合至捕获探针的组合物和方法
US6228589B1 (en) Measurement of gene expression profiles in toxicity determination
US6413723B1 (en) Methods and compositions for identifying nucleic acids containing cis acting elements
JP2007014297A (ja) 細胞構成物質分取チップならびに細胞構成物質解析システム及びこれらを用いる細胞構成物質解析法
AU4170500A (en) Upa, a universal protein array system
EA006425B1 (ru) Система для определения одной или нескольких мишеней в образце и способы ее применения
WO1997013877A1 (fr) Mesure de profils d'expression genique pour evaluer la toxicite
ES2423598T3 (es) Selección y aislamiento de células vivas usando sondas que se unen a ARNm
JPWO2003062418A1 (ja) 核酸情報の検出方法及び装置
US20230175047A1 (en) Array and method for detecting spatial information of nucleic acids
EP2130913A1 (fr) Puce d'échantillonnage d'un composant de cellule, système d'analyse d'un composant de cellule et procédé d'analyse d'un composant de cellule au moyen de celui-ci
US6448387B1 (en) Polymeric arrays adapted for high expressing polynucleotides
US7115369B2 (en) Functional nucleic acid probes and uses thereof
US20230227809A1 (en) Multiplex Chromatin Interaction Analysis with Single-Cell Chia-Drop
EP1194573A2 (fr) Arrangements nucleotidiques catalytiques ou pre-catalytiques
CN101663406A (zh) 用于得到未知生物分子和单链核酸的结合谱的核酸芯片及其制备方法和利用该核酸芯片分析未知生物分子的方法
US9416401B2 (en) Method for determining amounts of polynucleotide sequences present in cell or tissue samples
WO2001044812A1 (fr) Methode d'analyse et de detection simultanees d'analytes multiples par micro-identification
JPH0670799A (ja) ハイブリダイゼーション法
JP2992632B1 (ja) Ｄｎａ断片の逐次切り出し方法及びそれを用いたｄｎａの解析方法
WO1998043088A1 (fr) Procede de realisation d'echantillotheque soustractive
CN116829729A (zh) 用于捕获探针和/或条形码的方法、组合物和系统

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09601215

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 506860

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000939029

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000939029

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000939029

Country of ref document: EP